Results for tag: "Transitional Cell Carcinoma Drug"

Transitional Cell Carcinoma (TCC) is a type of kidney cancer that affects the lining of the urinary tract. It is the most common type of bladder cancer and is often treated with chemotherapy, radiation, and surgery. Drug treatments for TCC include targeted therapies, immunotherapies, and chemotherapy. Targeted therapies are designed to target specific molecules in cancer cells, while immunotherapies use the body’s own immune system to fight cancer. Chemotherapy is a type of drug treatment that uses drugs to kill cancer cells. The TCC drug market is a rapidly growing segment of the kidney cancer drug market. It is driven by the increasing prevalence of TCC, the development of new drugs, and the increasing demand for personalized treatments. The market is expected to continue to grow in the coming years as new treatments are developed and approved. Some of the major companies in the TCC drug market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more